Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.

ABSTRACT:

Objective

To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists).

Methods

Cross-sectional surveys of OAB patients and OAB-treating physicians in the USA were conducted. Patients receiving monotherapy with antimuscarinics were categorized by OAB treatment history: monotherapy only; third-line procedures (e.g., onabotulinumtoxinA injections) and combination therapy; third-line therapy only; and combination therapy only. The patient survey assessed therapy choice drivers and barriers, treatment satisfaction and sociodemographic/clinical characteristics. The physician survey assessed drivers of and barriers to OAB treatment choices.

Results

Of 200 patients, 86.5% reported invol

SUBMITTER: Kraus SR 

PROVIDER: S-EPMC9127871 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature